ISCO.OB is focused on using hpSC to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven … clinically … yet is limited by the availability of safe immune-matched human cells. ISCO.OB is about to demonstrate the therapeutic applicability and potential immune rejection advantages of hpSC lines relative to other stem cell classes. Its new production facility for clinical-grade stem cell products has passed final building inspection consisting of separate suites to further develop and produce different cell types from the their human parthenogenic stem cell (hpSC) technology. These parthenogenetic stem cells have the medical advantage of allowing immune-matching to large segments of the population and the ethical advantage of not requiring the use of human embryos.
Reiterating, ISCO.OB has developed a new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection.
- Human parthenogenetic stem cells have therapeutic potential,
- Parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpSC) that could be immune-matched,
- Like hESCs, hpSCs are pluripotent yet avoid ethical issues associated with destruction or use of viable human embryos,
- Unlike iPSCs, hpSCs do not require manipulation of gene expression back to a less differentiated stage, which may prove to be a safety or regulatory obstacle,
- Unlike both ESCs and iPSCs, hpSCs can be created in a homozygous form such that each line can be an immunological match for millions of patients,
- While researchers are ecstatic with the new outlook on hESC-based research, many have voiced concerns over the decision to prevent funding for cell lines created through parthogenesis as well as another technique called somatic cell nuclear transfer,
- The NIH states that the guidelines reflect the fact that there is no clear consensus … yet … about the ethical process.